Calcium channel blockers and beta-blockers stand out as the two major antihypertensive classes with the lowest risk of dragging sodium levels down. A large Swedish case-control study found that ongoing calcium channel blocker therapy was actually associated with a reduced odds of severe hyponatremia, while thiazide and thiazide-like diuretics remain the dominant culprits. The picture is more layered than a simple safe-versus-dangerous list, though, because the timing of treatment, the patient’s individual risk profile, and what other medications are on board all shape the outcome.
Thiazides Are the Primary Offenders
If you are looking for the blood pressure drug most likely to cause low sodium, the answer is unambiguous. Thiazide and thiazide-like diuretics are recognized as the leading cause of severe and very severe drug-induced hyponatremia.1PubMed Central. Drug-Induced Hyponatremia: Insights into Pharmacological Mechanisms and Clinical Practice Management A ten-year pharmacovigilance study tracking cases of dangerously low sodium found that drugs were the primary cause, and that the rate of the most severe cases tripled over the study period.2PubMed. Severe Hyponatremia Is Often Drug Induced: 10-Year Results of a Prospective Pharmacovigilance Program Thiazides dominate the drug-induced category because of how they interfere with the kidney’s ability to handle water. They impair the kidney’s diluting function, promote sodium and potassium loss in the urine, and can stimulate the release of antidiuretic hormone, which tells the body to hold onto water.3The American Journal of the Medical Sciences. Severe Hyponatremia Associated With Combined Thiazide Diuretic and Selective Serotonin Reuptake Inhibitor Therapy Some evidence also points to an increase in thirst, causing patients to drink more fluid than they can appropriately excrete.4PubMed Central. Thiazide-induced hyponatremia
Common thiazide and thiazide-like drugs include hydrochlorothiazide, chlorthalidone, indapamide, and metolazone. All share the same basic problem. If you are currently taking one and have been told your sodium is low, this is the first medication your doctor will look at.
Loop Diuretics Are a Different Story
People sometimes assume all diuretics are equally dangerous for sodium, but loop diuretics like furosemide behave differently. A review of 129 published cases of diuretic-induced severe hyponatremia found that roughly 63 percent involved a thiazide, another 10 percent involved chlorthalidone, and 20 percent involved a thiazide combined with a potassium-sparing agent. Only about 6 percent of cases were attributed to furosemide.5CHEST. Diuretic-induced Severe Hyponatremia Review and Analysis of 129 Reported Patients This is a striking difference, and it matters clinically. Loop diuretics are much less likely to cause symptomatic hyponatremia compared to thiazides.6International Journal of Cardiology and Cardiovascular Disorder. Thiazide Diuretics Induced Refractory Hyponatremia: Use of Vaptans
The reason comes down to where in the kidney each drug acts. Thiazides block sodium reabsorption in the distal tubule, which is the part of the kidney responsible for fine-tuning urine dilution. That impairs the kidney’s ability to produce dilute urine, so excess water gets retained in the body. Loop diuretics, by contrast, work earlier in the nephron, at the loop of Henle, where they interfere with both concentrating and diluting mechanisms. The net result is that loop diuretics tend to cause water loss along with sodium loss, rather than trapping water the way thiazides do. For patients who genuinely need a diuretic but are at risk for low sodium, switching from a thiazide to a loop diuretic is one of the standard approaches.
Calcium Channel Blockers
Among the non-diuretic antihypertensive classes, calcium channel blockers have the most reassuring data. In a large Swedish population-based study, patients on ongoing calcium channel blocker therapy had a lower odds of severe hyponatremia than the general hypertensive population, with an adjusted odds ratio of about 0.81.7PubMed Central. Associations Between Antihypertensive Medications and Severe Hyponatremia: A Swedish Population–Based Case–Control Study That is not just a neutral result; it is a protective signal, though the study design cannot prove causation.
There is a wrinkle worth understanding, though. In that same study, newly initiated calcium channel blockers did show a temporarily elevated risk, with an adjusted odds ratio of about 1.65 for the first period of use. The same pattern held for every drug class examined. This likely reflects something called “confounding by indication”: patients who just started a new blood pressure drug may have had a recent health event, changes in fluid status, or other disruptions that predispose them to sodium problems. Once therapy was established, the risk settled below baseline. The vascular subtype of calcium channel blockers, such as amlodipine and nifedipine, showed a similarly protective pattern during ongoing use.
Beta-Blockers
Beta-blockers are another class with a low hyponatremia risk. While the Swedish study focused specifically on four drug classes (calcium channel blockers, ACE inhibitors, ARBs, and thiazides) rather than beta-blockers directly, beta-blockers have not been identified as a drug class that promotes hyponatremia in pharmacovigilance data or clinical reviews. They work by slowing the heart rate and reducing the force of contraction, mechanisms that do not interfere with kidney sodium handling or antidiuretic hormone release. Drugs like metoprolol, atenolol, and bisoprolol are widely used and are not flagged in the hyponatremia literature the way thiazides and even some other classes are.
That said, beta-blockers are rarely used as first-line therapy for uncomplicated high blood pressure anymore. They tend to be prescribed when there is a second reason to use them, such as a fast heart rate, heart failure, or a history of heart attack. So while they are reassuring from a sodium standpoint, the decision to use one usually hinges on other clinical factors.
ACE Inhibitors and ARBs Carry a Small but Real Risk
Angiotensin-converting enzyme inhibitors (like lisinopril and ramipril) and angiotensin receptor blockers (like losartan and valsartan) are among the most commonly prescribed blood pressure medications worldwide. Their relationship with hyponatremia is less clean-cut than calcium channel blockers. The Swedish study found that ongoing ARB therapy had an adjusted odds ratio of about 1.08 for severe hyponatremia, hovering right around the neutral mark. For newly started ACE inhibitors, the risk was more clearly elevated, with an adjusted odds ratio of roughly 2.24 during the initiation period.7PubMed Central. Associations Between Antihypertensive Medications and Severe Hyponatremia: A Swedish Population–Based Case–Control Study
A small pilot study found that hyponatremia developed in about half of patients taking ACE inhibitors and roughly a third of those on ARBs, although the study was too small to confirm a statistically significant difference between the two.8Journal of Clinical and Diagnostic Research. Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study This does not mean ACE inhibitors are dangerous, but it does suggest they are not as sodium-neutral as calcium channel blockers. Both ACE inhibitors and ARBs can stimulate antidiuretic hormone through their effects on the renin-angiotensin system, which may explain the modest signal. The risk is much smaller than with thiazides, and in most patients it never becomes clinically relevant. Still, in someone who has already had an episode of hyponatremia, it is worth noting.
Mineralocorticoid Receptor Antagonists
Spironolactone and its newer relatives, eplerenone and finerenone, are used for resistant hypertension, heart failure, and some hormonal conditions. They work differently from thiazides, blocking the effects of the hormone aldosterone in the kidney. Despite that different mechanism, they are not free of hyponatremia risk. A pharmacovigilance analysis of adverse event reports found that spironolactone had a notably high number of hyponatremia reports, while eplerenone and finerenone had far fewer.9PubMed Central. Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis Pharmacovigilance data reflects what clinicians choose to report rather than true incidence rates, so it is not the same as a controlled trial. But spironolactone’s signal is strong enough to warrant attention, particularly in older adults or those already on other sodium-lowering medications.
The review of 129 severe hyponatremia cases attributed to diuretics found only a single case linked to spironolactone alone, though spironolactone was frequently used in combination with thiazides, where the thiazide was considered the primary cause.5CHEST. Diuretic-induced Severe Hyponatremia Review and Analysis of 129 Reported Patients That context matters: much of spironolactone’s hyponatremia signal may come from the company it keeps in combination regimens rather than from the drug acting solo.
SGLT2 Inhibitors May Actually Raise Sodium
One of the more interesting developments in this space involves SGLT2 inhibitors, a class originally developed for diabetes but now widely used for heart failure and kidney disease. Drugs like empagliflozin, dapagliflozin, and canagliflozin work by causing the kidneys to excrete glucose in the urine, and they pull water along with it. That osmotic diuresis promotes a net loss of free water relative to sodium, which is the opposite of what thiazides do.
Clinical data suggest that SGLT2 inhibitors can actually raise serum sodium levels, and a review of the evidence to date concluded they appear to be effective in the treatment of hyponatremia itself.10PubMed. A profile of SGLT-2 inhibitors in hyponatremia: The evidence to date A separate review categorized SGLT2 inhibitors alongside loop diuretics as drugs that promote a negative water balance and appear to decrease hyponatremia risk.11European Journal of Internal Medicine. Drug-induced hyponatremia: Causes, mechanisms, and clinical implications This makes SGLT2 inhibitors an attractive option for patients who need additional blood pressure or cardiorenal protection and have a history of low sodium. They are not yet a standard first-line antihypertensive for the general population, but in the right patient they solve two problems at once.
Who Is Most Vulnerable to Drug-Induced Hyponatremia
The risk of developing low sodium on any given medication is not evenly distributed. Certain patient characteristics dramatically increase susceptibility, particularly when thiazides are involved. A study looking at clinical and genetic predictors of thiazide-induced hyponatremia identified four independent risk factors:
- Older age: each additional year of age raised the odds by about 13 percent.
- Female sex: women had roughly four and a half times the odds of developing hyponatremia on a thiazide compared to men.
- Lower body weight: a lower body mass index increased susceptibility, likely because smaller people have a smaller total body water pool to dilute.
- Genetic variation: a specific polymorphism in the KCNJ1 gene, which encodes a potassium channel in the kidney, increased the odds nearly sixfold.
These factors were identified through multivariate analysis, meaning each one held up independently of the others.12PubMed Central. Clinical and Genetic Factors Associated With Thiazide-Induced Hyponatremia The genetic finding is worth pausing on. Most clinicians do not test for KCNJ1 variants before prescribing a thiazide, and routine genetic screening for this purpose is not yet standard practice. But it illustrates that some people are biologically wired to handle thiazides poorly, and their hyponatremia is not just a matter of dose or duration.
Practically, this means an older woman with a small frame who is starting a thiazide for the first time deserves closer monitoring of her sodium levels, especially in the first few weeks. A young man with a higher body mass starting the same drug faces a fraction of that risk.
The Combination That Deserves Special Attention
Drug-induced hyponatremia is rarely about a single medication acting alone. Polypharmacy, the use of multiple drugs at once, is where the risk compounds. The combination that stands out most clearly in the literature is a thiazide diuretic taken alongside a selective serotonin reuptake inhibitor, the most common class of antidepressant. SSRIs independently affect sodium levels by stimulating antidiuretic hormone release, and when you add a thiazide on top, both drugs push sodium in the same downward direction.
A large study evaluating this interaction found that among SSRI users, concurrent thiazide use raised the odds of hyponatremia by about 24 percent. Among thiazide users, concurrent SSRI exposure raised the odds by about 27 percent.13PubMed Central. Evaluation of hyponatremia among older adults exposed to selective serotonin reuptake inhibitors and thiazide diuretics Those numbers may sound modest in isolation, but they apply on top of whatever baseline risk each drug already carries. In an older woman on both medications, the cumulative probability becomes clinically meaningful.
This matters because the overlap between depression and hypertension is enormous, particularly in older adults. Millions of people are on both drug classes simultaneously. If you are one of them and your sodium has been drifting low, the combination is the first thing to reconsider. Switching the thiazide to a calcium channel blocker or a loop diuretic eliminates one of the two offending mechanisms without touching the antidepressant.
What Happens When Sodium Drops in Someone on a Blood Pressure Drug
Mild drops in sodium are common and often go unnoticed. The trouble starts when levels fall further. Symptoms progress from vague complaints like fatigue, nausea, and headache to confusion, unsteadiness, and eventually seizures or loss of consciousness in severe cases. One of the insidious features of drug-induced hyponatremia is that it tends to develop slowly, over days to weeks, so the brain partially adapts. That means the person may not feel dramatically ill even at sodium levels that would be dangerous if they had developed acutely. This slow adaptation is protective in the short term but creates a different hazard: the symptoms get attributed to aging, to the underlying condition being treated, or to some other medication. Falls in older adults are a classic presentation that often gets investigated for neurological causes before anyone checks a basic metabolic panel.
In patients with chronic kidney disease, the consequences of even mild hyponatremia extend further. Data from a large cohort of kidney disease patients treated with diuretics showed that sodium below 135 was associated with a roughly 45 percent higher risk of progressing to the point of needing dialysis or a kidney transplant.14PubMed Central. Hyponatremia is Associated with Fluid Imbalance and Adverse Renal Outcome in Chronic Kidney Disease Patients Treated with Diuretics Whether hyponatremia directly causes worse kidney outcomes or merely signals a sicker patient is still debated, but either way, keeping sodium in range matters.
Putting a Practical Hierarchy Together
If you are trying to manage blood pressure while minimizing hyponatremia risk, the evidence supports a rough ranking. At the safest end are calcium channel blockers like amlodipine, which show a protective signal in large studies, and beta-blockers, which are not linked to sodium problems. ACE inhibitors and ARBs fall in the middle: not major offenders but not entirely neutral either, particularly during initiation. Loop diuretics carry far less risk than thiazides when a diuretic is necessary. And thiazides, especially in vulnerable patients, sit at the opposite end of the spectrum.
The ranking is not a substitute for clinical judgment. Blood pressure management often involves weighing multiple considerations at once, like kidney protection, heart failure, diabetic complications, and cost. An ACE inhibitor might be the right choice for someone with diabetic kidney disease even if a calcium channel blocker would be “safer” for sodium, because the kidney benefit outweighs the small sodium risk. The hierarchy becomes most useful in two situations: when someone has already had an episode of hyponatremia and the triggering drug needs to be replaced, and when a high-risk patient (older, female, low body weight, already on an SSRI) is starting antihypertensive therapy for the first time.
Genetic Screening and Future Directions
The discovery that specific gene variants can increase thiazide-induced hyponatremia risk by several-fold raises an obvious question: should we be testing people before prescribing these drugs? Right now, the answer from clinical practice is no, at least not routinely. The variants identified, including the KCNJ1 polymorphism, have been found in relatively small studies, and no major guideline yet recommends pharmacogenomic testing before starting a thiazide.12PubMed Central. Clinical and Genetic Factors Associated With Thiazide-Induced Hyponatremia But the principle is sound, and as genetic testing becomes cheaper and more integrated into routine care, it is easy to imagine a future where a simple panel flags someone as high-risk for thiazide-related sodium problems before the first pill is ever taken.
In the meantime, the clinical factors do a reasonable job of identifying who to watch. A prescriber who notices that a patient is an older woman with a low body mass, already on an SSRI, and about to start hydrochlorothiazide has enough information to think twice about that thiazide. Checking sodium a week or two after starting, and again a month later, catches most problems early. If sodium does drop, the switch to a calcium channel blocker, a loop diuretic, or, in selected patients, an SGLT2 inhibitor provides a path forward that preserves blood pressure control without the sodium penalty.